febuxostat has been researched along with Cardiovascular Diseases in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 33 (56.90) | 24.3611 |
| 2020's | 25 (43.10) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Konishi, M; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 1 |
| Gruber, F; Kossmeier, M; Leitner, S; Litschauer, B; Reichardt, B; Sibinovic, S; Weisshaar, S; Wolzt, M | 1 |
| Choi, J; Ghang, BZ; Kim, J; Lee, JS; Yoo, B | 1 |
| Meng, J; Xu, C | 1 |
| Iguchi, T; Ishiguro, C; Kajiyama, K; Kimura, R; Nakazato, Y; Oniyama, Y; Sawada, S; Shida, H; Uyama, Y | 1 |
| Choi, E; Jeong, H; Kim, B; Suh, A; Yoo, M | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kohagura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 1 |
| Mironova, OI | 1 |
| Bowers, MS; Cole, BK; Feaver, RE; Figler, RA; Henke, BR; Hoang, S; Johns, BA; LaMoreaux, BD; Lawson, MJ; Nyborg, AC; Taylor, J; Wamhoff, BR; Zhao, L | 1 |
| Ahn, SM; Ghang, B; Kim, J; Kim, YG; Lee, CK; Yoo, B | 1 |
| Asad, A; Batra, S; Ochani, RK; Yasmin, F | 1 |
| Cheung, BMY; Ho, J; Hung, JKF; Ju, C; Lai, JCL; Lai, RWC; Li, KHC; Liu, T; Liu, Y; Tam, LS; Tse, G; Tsoi, MF; Wong, ICK | 1 |
| Cao, L; Wan, WG; Xue, Y; Yang, X; Zhao, L; Zhao, TY; Zhu, XX; Zou, HJ | 1 |
| Alten, R; Mischkewitz, M; Nitschmann, S | 1 |
| Deng, H; Jin, HM; Tong, JD; Yang, XH; Zhang, BL | 1 |
| Desai, RJ; Kim, E; Kim, SC; Lii, J; Neogi, T | 1 |
| De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J | 1 |
| Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB | 1 |
| Bandyopadhyay, D; Deedwania, P; Fonarow, GC; Ghosh, RK; Gupta, M; Hajra, A; Kaul, S; Klein, A; Lavie, CJ; Mamas, M; Roddy, E | 1 |
| Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK | 1 |
| Charlton, A; MacMullan, PA | 1 |
| Desai, RJ; Kim, E; Kim, SC; Liu, J; Pawar, A | 1 |
| de Jong, ICA; Rongen, GA; van der Pol, KH; van Herwaarden, N | 1 |
| Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L | 1 |
| Pope, JE; Zhang, T | 1 |
| Alshahawey, M; Elsaid, TW; Sabri, NA; Shahin, SM | 1 |
| Abe, K; Kanno, S; Obata, K; Sekino, H; Sezai, A | 1 |
| Ishii, T; Oyama, K; Taguri, M; Tamura, K | 1 |
| Aschenbrenner, DS | 1 |
| Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB | 1 |
| Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Saag, K; Whelton, A | 1 |
| Choi, H; Dalbeth, N; Neogi, T; Stamp, L; Terkeltaub, R | 1 |
| Desai, RJ; Kang, EH; Kim, SC; Liu, J; Neogi, T; Solomon, DH; Zhang, M | 1 |
| Müller-Wieland, D; Nitschmann, S | 1 |
| Kuwabara, M | 2 |
| White, WB | 1 |
| Jansen, TLTA; Janssen, M | 1 |
| Abeles, AM; Pillinger, MH | 1 |
| Chang, CJ; Chang, YC; Chen, CB; Chen, CH; Chen, SM; Chen, WT; Chi, CC; Chung, WH; Hsu, LA; Hung, SI; Lin, KM; Lin, YJ; Lu, CW; Pan, RY; Su, SC; Wang, CW; Wu, YJ; Yu, KH | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 2 |
| Gupta, MK; Singh, JA | 1 |
| Masi, S; Pugliese, NR; Taddei, S | 1 |
| Choi, HK; Kang, EH; Kim, SC; Lee, EB; Lee, YJ; Shin, A; Song, YW | 1 |
| Burnier, M; Messerli, FH | 1 |
| Hsieh, SC; Lin, FJ; Lin, LY; Shen, LJ; Su, CY | 1 |
| Kang, EH; Kim, SC | 1 |
| Hasegawa, K; Hiramitsu, S; Ishiguro, Y; Ishii, J; Kani, A; Kato, H; Kato, K; Kato, Y; Kimura, H; Matsubara, S; Matsubara, Y; Matsuyama, H; Mori, K; Noba, M; Shino, K; Tokuda, M; Uchiyama, T; Uemura, A; Yamada, K; Yoshida, S | 1 |
| Bocale, R; Desideri, G; Ferri, C; Grassi, D; Pontremoli, R | 1 |
| Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W | 1 |
| De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; Jennings, CG; MacDonald, TM; Mackenzie, IS; McMurray, J; Nuki, G; Perez Ruiz, F; Ralston, S; Walters, M; Webster, J | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Julkunen, H; Konttinen, YT | 1 |
| Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA | 1 |
| Chohan, S; Dabholkar, A; Hunt, B; Jackson, R; White, WB | 1 |
13 review(s) available for febuxostat and Cardiovascular Diseases
| Article | Year |
|---|---|
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2021 |
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid | 2023 |
Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Humans; Hyperuricemia; Risk Assessment; Uric Acid | 2020 |
Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials.
Topics: Cardiovascular Diseases; Death; Febuxostat; Gout; Humans; Randomized Controlled Trials as Topic | 2021 |
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.
Topics: Cardiovascular Diseases; Colchicine; COVID-19; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Pandemics | 2021 |
The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Topics: Allopurinol; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid | 2021 |
Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Topics: Adult; Allopurinol; Arthritis, Gouty; Cardiovascular Diseases; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome; Urate Oxidase | 2017 |
[Cardiovascular risk in gout patients : Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Risk Factors | 2018 |
Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population-Based Cohort Study and Meta-Analysis.
Topics: Aged; Allopurinol; Asian People; Cardiovascular Diseases; Cohort Studies; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Febuxostat; Gout; Gout Suppressants; Humans; Middle Aged; Taiwan | 2019 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid | 2019 |
Cardiovascular Safety of Urate Lowering Therapies.
Topics: Allopurinol; Cardiovascular Diseases; Endothelium; Febuxostat; Gout; Gout Suppressants; Heart Failure; Humans; Hypertension; Hyperuricemia; Myocardial Infarction; Probenecid; Risk; Stroke; Uricosuric Agents; Xanthine Oxidase | 2019 |
Therapeutic approaches to chronic hyperuricemia and gout.
Topics: Allopurinol; Cardiovascular Diseases; Chronic Disease; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Life Style; Patient Education as Topic; Thiazoles; Xanthine Oxidase | 2014 |
[The clinical picture of gout is changing].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Risk Factors; Thiazoles; Uricosuric Agents | 2010 |
16 trial(s) available for febuxostat and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome | 2022 |
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Topics: Aged; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2023 |
Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Heart Disease Risk Factors; Humans; Risk Factors; United States; Xanthine Oxidase | 2023 |
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Denmark; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Prospective Studies; Sweden; Treatment Outcome; United Kingdom; Uric Acid | 2020 |
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Topics: Adult; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Pulse Wave Analysis; Risk Factors; Thiazoles; Treatment Outcome; Uric Acid | 2022 |
Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study.
Topics: Administration, Oral; Adult; Alanine Transaminase; Arginine; Aspartate Aminotransferases; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Febuxostat; Female; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Pancytopenia; Placebos; Prospective Studies; Renal Dialysis; Risk Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Topics: Adult; Aged; Anti-Inflammatory Agents; Antioxidants; Cardiovascular Diseases; Cross-Over Studies; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Nitriles; Pyridines; Treatment Outcome; Uric Acid | 2017 |
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged | 2018 |
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Topics: Aged; Cardiovascular Diseases; Delayed-Action Preparations; Double-Blind Method; Febuxostat; Female; Gastrointestinal Diseases; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Middle Aged; Treatment Outcome | 2018 |
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Prospective Studies; Uric Acid | 2019 |
Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Prevalence; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prospective Studies; Research Design | 2014 |
Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Renin-Angiotensin System; Risk Factors; Treatment Outcome; Xanthine Oxidase | 2015 |
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Topics: Aged; Aged, 80 and over; Brain Diseases; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Research Design; Single-Blind Method; Treatment Outcome; Uric Acid | 2017 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Illinois; Male; Metabolic Diseases; Middle Aged; Obesity; Retrospective Studies; Sex Factors; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2012 |
Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
Topics: Allopurinol; Cardiovascular Diseases; Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Prospective Studies; Thiazoles | 2012 |
29 other study(ies) available for febuxostat and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Hyperuricemia; Ischemic Stroke; Male; Retrospective Studies; Risk Factors; Uric Acid | 2022 |
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.
Topics: Allopurinol; Cardiovascular Diseases; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans | 2022 |
Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Secondary Prevention; Treatment Outcome | 2023 |
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Insurance, Health; Japan; Risk Factors; Treatment Outcome; Uric Acid | 2023 |
`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.
Topics: Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Republic of Korea; Retrospective Studies | 2023 |
Safety update: febuxostat and CVD.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2023 |
Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial.
Topics: Adult; Allopurinol; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; Withholding Treatment | 2020 |
A word of caution regarding Febuxostat.
Topics: Allopurinol; Cardiovascular Diseases; Drug-Related Side Effects and Adverse Reactions; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Pakistan; Xanthine Oxidase | 2019 |
Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Male; Middle Aged; Retrospective Studies; Xanthine Oxidase | 2020 |
[Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Morbidity | 2020 |
Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat.
Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Drug Labeling; Febuxostat; Gout; Gout Suppressants; Humans; Mortality; Polyethylene Glycols; Practice Patterns, Physicians'; Probenecid; Risk Factors; Thioglycolates; Triazoles; United States; United States Food and Drug Administration; Urate Oxidase | 2021 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2021 |
Is Febuxostat Use Associated With Increased Risk of Cardiovascular Disease Events? The Answer Is Crystal Clear.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans | 2021 |
Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Incidence; Male; Retrospective Studies; Risk Assessment; Survival Rate; United States | 2021 |
[Cardiovascular risk in gout - Role of allopurinol?]
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Male; Risk Factors | 2021 |
Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Incidence; Kidney Failure, Chronic; Male; Models, Structural; Prognosis; Renal Dialysis; Risk Factors; Survival Rate; Uric Acid; Xanthine Dehydrogenase | 2017 |
Risk of Heart-Related Death From Gout Medication.
Topics: Cardiovascular Diseases; Cause of Death; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; United States; United States Food and Drug Administration | 2018 |
New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Topics: Allopurinol; Cardiovascular Diseases; Comorbidity; Enzyme Inhibitors; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Mortality; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Xanthine Oxidase | 2018 |
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cause of Death; Databases, Factual; Febuxostat; Female; Gout; Hospitalization; Humans; Hyperuricemia; Male; Medicare; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
Febuxostat Does Not Increase All-Cause Mortality and Cardiovascular Mortality Compared With Placebo: Comment on the Article by Choi et al.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States Food and Drug Administration | 2019 |
Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Risk Factors; Xanthine Oxidase | 2018 |
Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.
Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Randomized Controlled Trials as Topic; Risk Factors | 2019 |
Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et al.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; Risk Factors; United States Food and Drug Administration | 2019 |
Letter by Kuwabara Regarding Article, "Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study".
Topics: Aged; Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Patients; Population; Risk Factors | 2019 |
The difficult relationship between uric acid and cardiovascular disease.
Topics: Aged; Allopurinol; Atrial Fibrillation; Cardiovascular Diseases; Febuxostat; Humans; Medicare; Risk Factors; United States; Uric Acid | 2019 |
Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Republic of Korea; Stroke | 2019 |
Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?
Topics: Cardiovascular Diseases; Drug Labeling; Febuxostat; Humans; Thiazoles; Uric Acid | 2019 |
Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Databases, Factual; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Retrospective Studies; Risk Factors; Taiwan | 2019 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid; Uricosuric Agents; Urolithiasis | 2014 |